Structural insight into proteolytic activation and regulation of the complement system

Immunological Reviews

Volumn 274, Issue 1, 2016, Pages 59-73

  Schatz Jakobsen, Janus A ^a   Pedersen, Dennis V ^a   Andersen, Gregers R ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

complement; immune disorders; proteolytic cascade; structural biology

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5B; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; ECULIZUMAB; FICOLIN; LECTIN; MANNAN BINDING LECTIN; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR; PROPERDIN; COMPLEMENT; MULTIPROTEIN COMPLEX;

COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT LECTIN PATHWAY; COMPLEMENT SYSTEM; COMPLEX FORMATION; CRYSTALLOGRAPHY; ELECTRON MICROSCOPY; HUMAN; IMMUNOREGULATION; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN QUATERNARY STRUCTURE; PROTEIN STRUCTURE; REVIEW; X RAY CRYSTALLOGRAPHY; ANIMAL; GENETICS; IMMUNE SYSTEM DISEASES; IMMUNOLOGY; METABOLISM; MUTATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNE SYSTEM DISEASES; MULTIPROTEIN COMPLEXES; MUTATION; PROTEOLYSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84992451593     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12465     Document Type: Review

References (136)

1. Bajic G, Degn SE, Thiel S, Andersen GR. Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J. 2015;34:2735–2757.
2. Diebolder CA, Beurskens FJ, de Jong RN, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014;343:1260–1263.
3. Serna M, Giles JL, Morgan BP, Bubeck D. Structural basis of complement membrane attack complex formation. Nat Commun. 2016;7:10587.
4. Sharp TH, Koster AJ, Gros P. Heterogeneous MAC initiator and pore structures in a lipid bilayer by phase-plate cryo-electron tomography. Cell Rep. 2016;15:1–8.
5. Degn SE, Kjaer TR, Kidmose RT, et al. Complement activation by ligand-driven juxtaposition of discrete pattern recognition complexes. Proc Natl Acad Sci USA. 2014;111:13445–13450.
6. Degn SE, Thiel S. Humoral pattern recognition and the complement system. Scand J Immunol. 2013;78:181–193.
7. Henriksen ML, Brandt J, Andrieu JP, et al. Heteromeric complexes of native collectin kidney 1 and collectin liver 1 are found in the circulation with MASPs and activate the complement system. J Immunol. 2013;191:6117–6127.
8. Kjaer TR, Thiel S, Andersen GR. Toward a structure-based comprehension of the lectin pathway of complement. Mol Immunol. 2013;56:222–231.
9. Degn SE, Jensen L, Hansen AG, et al. Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway function. J Immunol. 2012;189:3957–3969.
10. Heja D, Kocsis A, Dobo J, et al. Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2. Proc Natl Acad Sci USA. 2012;109:10498–10503.
11. Gingras AR, Girija UV, Keeble AH, et al. Structural basis of mannan-binding lectin recognition by its associated serine protease MASP-1: implications for complement activation. Structure. 2011;19:1635–1643.
12. Lacroix M, Dumestre-Perard C, Schoehn G, et al. Residue Lys57 in the collagen-like region of human L-ficolin and its counterpart Lys47 in H-ficolin play a key role in the interaction with the mannan-binding lectin-associated serine proteases and the collectin receptor calreticulin. J Immunol. 2009;182:456–465.
13. Teillet F, Lacroix M, Thiel S, et al. Identification of the site of human mannan-binding lectin involved in the interaction with its partner serine proteases: the essential role of Lys55. J Immunol. 2007;178:5710–5716.
14. Gal P, Harmat V, Kocsis A, et al. A true autoactivating enzyme. Structural insight into mannose-binding lectin-associated serine protease-2 activations. J Biol Chem. 2005;280:33435–33444.
15. Megyeri M, Harmat V, Major B, et al. Quantitative characterization of the activation steps of mannan-binding lectin (MBL)-associated serine proteases (MASPs) points to the central role of MASP-1 in the initiation of the complement lectin pathway. J Biol Chem. 2013;288:8922–8934.
16. Perry AJ, Wijeyewickrema LC, Wilmann PG, et al. A molecular switch governs the interaction between the human complement protease C1s and its substrate, complement C4. J Biol Chem. 2013;288:15821–15829.
17. Skjoedt MO, Roversi P, Hummelshoj T, et al. Crystal structure and functional characterization of the complement regulator mannose-binding lectin (MBL)/ficolin-associated protein-1 (MAP-1). J Biol Chem. 2012;287:32913–32921.
18. Wallis R, Mitchell DA, Schmid R, Schwaeble WJ, Keeble AH. Paths reunited: initiation of the classical and lectin pathways of complement activation. Immunobiology. 2010;215:1–11.
19. Teillet F, Gaboriaud C, Lacroix M, Martin L, Arlaud GJ, Thielens NM. Crystal structure of the CUB1-EGF-CUB2 domain of human MASP-1/3 and identification of its interaction sites with mannan-binding lectin and ficolins. J Biol Chem. 2008;283:25715–25724.
20. Kjaer TR, Le le TM, Pedersen JS, et al. Structural insights into the initiating complex of the lectin pathway of complement activation. Structure. 2015;23:342–351.
21. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I – molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.
22. Kojouharova M, Reid K, Gadjeva M. New insights into the molecular mechanisms of classical complement activation. Mol Immunol. 2010;47:2154–2160.
23. Kouser L, Madhukaran SP, Shastri A, et al. Emerging and novel functions of complement protein C1q. Front Immunol. 2015;6:317.
24. Lui H, Zhang J, Makinson SR, et al. Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell. 2016;165:921–935.
25. Hong S, Beja-Glasser VF, Nfonoyim BM, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712–716.
26. Bialas AR, Stevens B. TGF-beta signaling regulates neuronal C1q expression and developmental synaptic refinement. Nat Neurosci. 2013;16:1773–1782.
27. Kilchherr E, Hofmann H, Steigemann W, Engel J. Structural model of the collagen-like region of C1q comprising the kink region and the fibre-like packing of the six triple helices. J Mol Biol. 1985;186:403–415.
28. Gaboriaud C, Juanhuix J, Gruez A, et al. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J Biol Chem. 2003;278:46974–46982.
29. Venkatraman Girija U, Gingras AR, Marshall JE, et al. Structural basis of the C1q/C1s interaction and its central role in assembly of the C1 complex of complement activation. Proc Natl Acad Sci USA. 2013;110:13916–13920.
30. Brier S, Pflieger D, Le Mignon M, et al. Mapping surface accessibility of the C1r/C1s tetramer by chemical modification and mass spectrometry provides new insights into assembly of the human C1 complex. J Biol Chem. 2010;285:32251–32263.
31. Budayova-Spano M, Lacroix M, Thielens NM, Arlaud GJ, Fontecilla-Camps JC, Gaboriaud C. The crystal structure of the zymogen catalytic domain of complement protease C1r reveals that a disruptive mechanical stress is required to trigger activation of the C1 complex. EMBO J. 2002;21:231–239.
32. Bally I, Ancelet S, Moriscot C, et al. Expression of recombinant human complement C1q allows identification of the C1r/C1s-binding sites. Proc Natl Acad Sci USA. 2013;110:8650–8655.
33. Bally I, Rossi V, Lunardi T, Thielens NM, Gaboriaud C, Arlaud GJ. Identification of the C1q-binding sites of human C1r and C1s: a refined three-dimensional model of the C1 complex of complement. J Biol Chem. 2009;284:19340–19348.
34. Schumaker VN, Zavodszky P, Poon PH. Activation of the first component of complement. Annu Rev Immunol. 1987;5:21–42.
35. Kardos J, Harmat V, Pallo A, et al. Revisiting the mechanism of the autoactivation of the complement protease C1r in the C1 complex: structure of the active catalytic region of C1r. Mol Immunol. 2008;45:1752–1760.
36. Dodds AW, Ren XD, Willis AC, Law SK. The reaction mechanism of the internal thioester in the human complement component C4. Nature. 1996;379:177–179.
37. Sekar A, Bialas AR, deRivera H, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530:177–183.
38. Kidmose RT, Laursen NS, Dobo J, et al. Structural basis for activation of the complement system by component C4 cleavage. Proc Natl Acad Sci USA. 2012;109:15425–15430.
39. Duncan RC, Mohlin F, Taleski D, et al. Identification of a catalytic exosite for complement component C4 on the serine protease domain of C1s. J Immunol. 2012;189:2365–2373.
40. Rodriguez E, Nan R, Li K, Gor J, Perkins SJ. A revised mechanism for the activation of complement C3 to C3b: a molecular explanation of a disease-associated polymorphism. J Biol Chem. 2015;290:2334–2350.
41. Mortensen S, Jensen JK, Andersen GR. Solution structures of complement C2 and its C4 complexes propose pathway specific mechanisms for control and activation of the complement proconvertases. J Biol Chem. 2016; pii: jbc.M116.722017.
42. Harboe M, Garred P, Karlstrom E, Lindstad JK, Stahl GL, Mollnes TE. The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification. Mol Immunol. 2009;47:373–380.
43. Harboe M, Ulvund G, Vien L, Fung M, Mollnes TE. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol. 2004;138:439–446.
44. Bexborn F, Andersson PO, Chen H, Nilsson B, Ekdahl KN. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3 (H 2 O) Bb). Mol Immunol. 2008;45:2370–2379.
45. Fishelson Z, Muller-Eberhard HJ. C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium. J Immunol. 1982;129:2603–2607.
46. Fearon DT, Austen KF. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med. 1975;142:856–863.
47. 2+) proconvertase. J Immunol. 2009;183:7347–7351.
48. Forneris F, Ricklin D, Wu J, et al. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science. 2010;330:1816–1820.
49. Janssen BJ, Gomes L, Koning RI, et al. Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex. EMBO J. 2009;28:2469–2478.
50. O'Keefe MC, Caporale LH, Vogel CW. A novel cleavage product of human complement component C3 with structural and functional properties of cobra venom factor. J Biol Chem. 1988;263:12690–12697.
51. Pan Q, Ebanks RO, Isenman DE. Two clusters of acidic amino acids near the NH2 terminus of complement component C4 alpha′-chain are important for C2 binding. J Immunol. 2000;165:2518–2527.
52. Milder FJ, Gomes L, Schouten A, et al. Factor B structure provides insights into activation of the central protease of the complement system. Nat Struct Mol Biol. 2007;14:224–228.
53. Wallis R, Dodds AW, Mitchell DA, Sim RB, Reid KB, Schwaeble WJ. Molecular interactions between MASP-2, C4, and C2 and their activation fragments leading to complement activation via the lectin pathway. J Biol Chem. 2007;282:7844–7851.
54. Zipfel PF, Hallstrom T, Riesbeck K. Human complement control and complement evasion by pathogenic microbes–tipping the balance. Mol Immunol. 2013;56:152–160.
55. Berends ET, Kuipers A, Ravesloot MM, Urbanus RT, Rooijakkers SH. Bacteria under stress by complement and coagulation. FEMS Microbiol Rev. 2014;38:1146–1171.
56. Rooijakkers SH, Wu J, Ruyken M, et al. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol. 2009;10:721–727.
57. Fearon DT, Austen KF. Properdin: initiation of alternative complement pathway. Proc Natl Acad Sci USA. 1975;72:3220–3224.
58. Carroll MV, Sim RB. Complement in health and disease. Adv Drug Deliv Rev. 2011;63:965–975.
59. Ritchie GE, Moffatt BE, Sim RB, Morgan BP, Dwek RA, Rudd PM. Glycosylation and the complement system. Chem Rev. 2002;102:305–320.
60. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol. 2004;5:981–986.
61. Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol. 2007;179:2600–2608.
62. Cortes C, Ferreira VP, Pangburn MK. Native properdin binds to Chlamydia pneumoniae and promotes complement activation. Infect Immun. 2011;79:724–731.
63. Gaarkeuken H, Siezenga MA, Zuidwijk K, et al. Complement activation by tubular cells is mediated by properdin binding. Am J Physiol Renal Physiol. 2008;295:F1397–F1403.
64. Zaferani A, Vives RR, van der Pol P, et al. Factor h and properdin recognize different epitopes on renal tubular epithelial heparan sulfate. J Biol Chem. 2012;287:31471–31481.
65. Kemper C, Hourcade DE. Properdin: new roles in pattern recognition and target clearance. Mol Immunol. 2008;45:4048–4056.
66. Xu W, Berger SP, Trouw LA, et al. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. J Immunol. 2008;180:7613–7621.
67. Saggu G, Cortes C, Emch HN, Ramirez G, Worth RG, Ferreira VP. Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O). J Immunol. 2013;190:6457–6467.
68. Kimura Y, Miwa T, Zhou L, Song WC. Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. Blood. 2008;111:732–740.
69. O'Flynn J, Dixon KO, Faber Krol MC, Daha MR, van Kooten C. Myeloperoxidase directs properdin-mediated complement activation. J Innate Immun. 2014;6:417–425.
70. Wang H, Wang C, Zhao MH, Chen M. Neutrophil extracellular traps can activate alternative complement pathways. Clin Exp Immunol. 2015;181:518–527.
71. Agarwal S, Ferreira VP, Cortes C, Pangburn MK, Rice PA, Ram S. An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae. J Immunol. 2010;185:507–516.
72. Kouser L, Abdul-Aziz M, Nayak A, Stover CM, Sim RB, Kishore U. Properdin and factor H: opposing players on the alternative complement pathway “see-saw”. Front Immunol. 2013;4:93.
73. Higgins JM, Wiedemann H, Timpl R, Reid KB. Characterization of mutant forms of recombinant human properdin lacking single thrombospondin type I repeats. Identification of modules important for function. J Immunol. 1995;155:5777–5785.
74. Sun Z, Reid K, Perkins SJ. The dimeric and trimeric solution structures of the multidomain complement protein properdin by X-ray scattering, analytical ultracentrifugation and constrained modelling. J Mol Biol. 2004;343:1327–1343.
75. Alcorlo M, Tortajada A, Rodriguez de Cordoba S, Llorca O. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin. Proc Natl Acad Sci USA. 2013;110:13504–13509.
76. Meri S, Pangburn MK. Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem Biophys Res Commun. 1994;198:52–59.
77. Aslam M, Perkins SJ. Folded-back solution structure of monomeric factor H of human complement by synchrotron X-ray and neutron scattering, analytical ultracentrifugation and constrained molecular modelling. J Mol Biol. 2001;309:1117–1138.
78. Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, Gros P. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol. 2009;10:728–733.
79. Morgan HP, Schmidt CQ, Guariento M, et al. Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol. 2011;18:463–470.
80. Kajander T, Lehtinen MJ, Hyvarinen S, et al. Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci USA. 2011;108:2897–2902.
81. Schmidt CQ, Herbert AP, Kavanagh D, et al. A new map of glycosaminoglycan and C3b binding sites on factor H. J Immunol. 2008;181:2610–2619.
82. Blackmore TK, Sadlon TA, Ward HM, Lublin DM, Gordon DL. Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H. J Immunol. 1996;157:5422–5427.
83. Ormsby RJ, Jokiranta TS, Duthy TG, et al. Localization of the third heparin-binding site in the human complement regulator factor H 1. Mol Immunol. 2006;43:1624–1632.
84. Roversi P, Johnson S, Caesar JJ, et al. Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc Natl Acad Sci USA. 2011;108:12839–12844.
85. Forneris F, Wu J, Xue X, et al. Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode. EMBO J. 2016;35:1133–1149.
86. Lee H, Whitfeld PL, Mackay CR. Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2. Immunol Cell Biol. 2008;86:153–160.
87. Rawal N, Pangburn MK. Functional role of the noncatalytic subunit of complement C5 convertase. J Immunol. 2000;164:1379–1385.
88. Rawal N, Pangburn MK. C5 convertase of the alternative pathway of complement. Kinetic analysis of the free and surface-bound forms of the enzyme. J Biol Chem. 1998;273:16828–16835.
89. Rawal N, Pangburn MK. Formation of high affinity C5 convertase of the classical pathway of complement. J Biol Chem. 2003;278:38476–38483.
90. Alper CA, Balavitch D. Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement). Science. 1976;191:1275–1276.
91. Vogel CW, Fritzinger DC. Cobra venom factor: structure, function, and humanization for therapeutic complement depletion. Toxicon. 2010;56:1198–1222.
92. Laursen NS, Magnani F, Gottfredsen RH, Petersen SV, Andersen GR. Structure, function and control of complement C5 and its proteolytic fragments. Curr Mol Med. 2012;12:1083–1097.
93. Laursen NS, Andersen KR, Braren I, Spillner E, Sottrup-Jensen L, Andersen GR. Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex. EMBO J. 2011;30:606–616.
94. Aleshin AE, DiScipio RG, Stec B, Liddington RC. Crystal structure of C5b-6 suggests structural basis for priming assembly of the membrane attack complex. J Biol Chem. 2012;287:19642–19652.
95. Hadders MA, Bubeck D, Roversi P, et al. Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9. Cell Rep. 2012;1:200–207.
96. Aleshin AE, Schraufstatter IU, Stec B, Bankston LA, Liddington RC, DiScipio RG. Structure of complement C6 suggests a mechanism for initiation and unidirectional, sequential assembly of membrane attack complex (MAC). J Biol Chem. 2012;287:10210–10222.
97. Yamamoto KI, Lint TF, Gewurz H. Enhancement of C56-initiated lysis by cell-bound C3 fragments: evidence for a mechanism independent of the prior binding of C56 to C3b. J Immunol. 1977;119:1346–1350.
98. Hammer CH, Abramovitz AS, Mayer MM. A new activity of complement component C3: cell-bound C3b potentiates lysis of erythrocytes by C5b,6 and terminal components. J Immunol. 1976;117:830–834.
99. Preissner KT, Podack ER, Muller-Eberhard HJ. The membrane attack complex of complement: relation of C7 to the metastable membrane binding site of the intermediate complex C5b-7. J Immunol. 1985;135:445–451.
100. Monahan JB, Sodetz JM. Role of the beta subunit in interaction of the eighth component of human complement with the membrane-bound cytolytic complex. J Biol Chem. 1981;256:3258–3262.
101. Bokisch VA, Muller-Eberhard HJ. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest. 1970;49:2427–2436.
102. Schatz-Jakobsen JA, Yatime L, Larsen C, Petersen SV, Klos A, Andersen GR. Structural and functional characterization of human and murine C5a anaphylatoxins. Acta Crystallogr D Biol Crystallogr. 2014;70:1704–1717.
103. Gerard C, Chenoweth DE, Hugli TE. Response of human neutrophils to C5a: a role for the oligosaccharide moiety of human C5ades Arg-74 but not of C5a in biologic activity. J Immunol. 1981;127:1978–1982.
104. Zuiderweg ER, Nettesheim DG, Mollison KW, Carter GW. Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance data. Biochemistry. 1989;28:172–185.
105. Fredslund F, Laursen NS, Roversi P, et al. Structure of and influence of a tick complement inhibitor on human complement component 5. Nat Immunol. 2008;9:753–760.
106. Zhang X, Boyar W, Toth MJ, Wennogle L, Gonnella NC. Structural definition of the C5a C terminus by two-dimensional nuclear magnetic resonance spectroscopy. Proteins. 1997;28:261–267.
107. Bajic G, Yatime L, Sim RB, Vorup-Jensen T, Andersen GR. Structural insight on the recognition of surface-bound opsonins by the integrin I domain of complement receptor 3. Proc Natl Acad Sci USA. 2013;110:16426–16431.
108. Ghassemian A, Wang CI, Yau MK, et al. Efficient chemical synthesis of human complement protein C3a. Chem Commun (Camb). 2013;49:2356–2358.
109. Cook WJ, Galakatos N, Boyar WC, Walter RL, Ealick SE. Structure of human desArg-C5a. Acta Crystallogr D Biol Crystallogr. 2010;66:190–197.
110. Schatz-Jakobsen JA, Zhang Y, Johnson K, Neill A, Sheridan D, Andersen GR. Structural basis for eculizumab-mediated inhibition of the complement terminal pathway. J Immunol. 2016;197:337–344.
111. Jore MM, Johnson S, Sheppard D, et al. Structural basis for therapeutic inhibition of complement C5. Nat Struct Mol Biol. 2016;23:378–386.
112. Yatime L, Maasch C, Hoehlig K, Klussmann S, Andersen GR, Vater A. Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA/L-DNA aptamer. Nat Commun. 2015;6:6481.
113. Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73:703–711.
114. Miyata T, Takeda J, Iida Y, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science. 1993;259:1318–1320.
115. Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124:2804–2811.
116. Brodsky RA. Complement in hemolytic anemia. Blood. 2015;126:2459–2465.
117. Nester CM, Barbour T, de Cordoba SR, et al. Atypical aHUS: state of the art. Mol Immunol. 2015;67:31–42.
118. Noris M, Remuzzi G. Atypical Hemolytic-Uremic Syndrome. N Engl J Med. 2009;361:1676–1687.
119. Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370:632–639.
120. Roversi P, Lissina O, Johnson S, et al. The structure of OMCI, a novel lipocalin inhibitor of the complement system. J Mol Biol. 2007;369:784–793.
121. Hepburn NJ, Williams AS, Nunn MA, et al. In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata. J Biol Chem. 2007;282:8292–8299.
122. Jongerius I, Kohl J, Pandey MK, et al. Staphylococcal complement evasion by various convertase-blocking molecules. J Exp Med. 2007;204:2461–2471.
123. Bestebroer J, Aerts PC, Rooijakkers SHM, Pandey MK, Köhl J, Strijp JAG. Functional basis for complement evasion by staphylococcal superantigen-like 7. Cell Microbiol. 2010;12:1506–1516.
124. Laursen NS, Gordon N, Hermans S, Lorenz N, Jackson N, Wines B. Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus. Proc Natl Acad Sci USA. 2010;107:3681–3686.
125. Langley R, Wines B, Willoughby N, Basu I, Proft T, Fraser JD. The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria. J Immunol. 2005;174:2926–2933.
126. Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov. 2015;14:857–877.
127. Vogt W, Schmidt G, Buttlar B, Dieminger L. A new function of the activated third component of complement: binding to C5, an essential step for C5 activation. Immunology. 1978;34:29–40.
128. Berends ET, Gorham RD Jr, Ruyken M, et al. Molecular insights into the surface-specific arrangement of complement C5 convertase enzymes. BMC Biol. 2015;13:93.
129. Takata Y, Kinoshita T, Kozono H, et al. Covalent association of C3b with C4b within C5 convertase of the classical complement pathway. J Exp Med. 1987;165:1494–1507.
130. Kim YU, Carroll MC, Isenman DE, et al. Covalent binding of C3b to C4b within the classical complement pathway C5 convertase. Determination of amino acid residues involved in ester linkage formation. J Biol Chem. 1992;267:4171–4176.
131. Hong K, Kinoshita T, Pramoonjago P, Kim YU, Seya T, Inoue K. Reconstitution of C5 convertase of the alternative complement pathway with isolated C3b dimer and factors B and D. J Immunol. 1991;146:1868–1873.
132. Kinoshita T, Takata Y, Kozono H, Takeda J, Hong KS, Inoue K. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme. J Immunol. 1988;141:3895–3901.
133. Mortensen S, Kidmose RT, Petersen SV, Szilagyi A, Prohaszka Z, Andersen GR. Structural basis for the function of complement component C4 within the classical and lectin pathways of complement. J Immunol. 2015;194:5488–5496.
134. Schmidt CQ, Bai H, Lin Z, et al. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J Immunol. 2013;190:5712–5721.
135. Klos A, Wende E, Wareham KJ, Monk PN. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev. 2013;65:500–543.
136. Katritch V, Cherezov V, Stevens RC. Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol. 2013;53:531–556.